Chemotherapy plus immunotherapy for EBV-positive stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy and an immunotherapy drug called toripalimab before and after surgery for a specific type of stomach cancer linked to the Epstein-Barr virus. It aims to see if this approach can improve treatment outcomes for patients with locally advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction adenocarcinoma.
- Your tumor tests positive for Epstein-Barr virus (EBV).
- Your cancer is locally advanced (spread to nearby tissues or lymph nodes, but not distant organs).
- You have not had prior treatment for this cancer (except biopsy).
- You are in good enough health with normal organ function.
- You can provide tissue samples for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy (a treatment that helps your immune system fight cancer) along with chemotherapy and radiation before surgery can help shrink tumors in people with stomach cancer at the esophagus-stomach junction. The goal is to see if this approach is safe and effective before the main surgery.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy for stomach cancer. The goal is to see if this combination can help shrink tumors and improve outcomes better than chemotherapy alone.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a new approach for locally advanced stomach cancer. It uses a heated chemotherapy bath (HIPEC) before giving a combination of two chemotherapy drugs (SOX or XELOX) plus an immunotherapy drug called serplulimab. This aims to shrink the tumor and improve the chances of successful surgery and long-term control.
This trial tests a combination of two treatments: an immunotherapy drug (pembrolizumab, which helps your immune system fight cancer) and chemotherapy (FLOT) for advanced stomach or esophageal junction cancer. The goal is to see if this combination is safe and works better than standard care.
Hear when a new Adenocarcinoma of Esophagogastric Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.